SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Hjorth Martin) ;pers:(Mahon Francois Xavier)"

Sökning: WFRF:(Hjorth Martin) > Mahon Francois Xavier

  • Resultat 1-6 av 6
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  •  
3.
  • Baccarani, Michele, et al. (författare)
  • European LeukemiaNet recommendations for the management of chronic myeloid leukemia : 2013
  • 2013
  • Ingår i: Blood. - : American Society of Hematology. - 0006-4971 .- 1528-0020. ; 122:6, s. 872-884
  • Forskningsöversikt (refereegranskat)abstract
    • Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase inhibitors, mandate regular updating of concepts and management. A European LeukemiaNet expert panel reviewed prior and new studies to update recommendations made in 2009. We recommend as initial treatment imatinib, nilotinib, or dasatinib. Response is assessed with standardized real quantitative polymerase chain reaction and/or cytogenetics at 3, 6, and 12 months. BCR-ABL1 transcript levels <= 10% at 3 months, <1% at 6 months, and <= 0.1% from 12 months onward define optimal response, whereas >10% at 6 months and >1% from 12 months onward define failure, mandating a change in treatment. Similarly, partial cytogenetic response (PCyR) at 3 months and complete cytogenetic response (CCyR) from 6 months onward define optimal response, whereas no CyR (Philadelphia chromosome-positive [Ph1]>95%) at 3 months, less than PCyR at 6 months, and less than CCyR from 12 months onward define failure. Between optimal and failure, there is an intermediate warning zone requiring more frequent monitoring. Similar definitions are provided for response to second-line therapy. Specific recommendations are made for patients in the accelerated and blastic phases, and for allogeneic stem cell transplantation. Optimal responders should continue therapy indefinitely, with careful surveillance, or they can be enrolled in controlled studies of treatment discontinuation once a deeper molecular response is achieved. (Blood. 2013; 122(6):872-884)
  •  
4.
  •  
5.
  •  
6.
  • Saussele, Susanne, et al. (författare)
  • Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI) : a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
  • 2018
  • Ingår i: The Lancet Oncology. - : Elsevier. - 1470-2045 .- 1474-5488. ; 19:6, s. 747-757
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Tyrosine kinase inhibitors (TKIs) have improved the survival of patients with chronic myeloid leukaemia. Many patients have deep molecular responses, a prerequisite for TKI therapy discontinuation. We aimed to define precise conditions for stopping treatment. Methods: In this prospective, non-randomised trial, we enrolled patients with chronic myeloid leukaemia at 61 European centres in 11 countries. Eligible patients had chronic-phase chronic myeloid leukaemia, had received any TKI for at least 3 years (without treatment failure according to European LeukemiaNet [ELN] recommendations), and had a confirmed deep molecular response for at least 1 year. The primary endpoint was molecular relapse-free survival, defined by loss of major molecular response (MMR; >0·1% BCR-ABL1 on the International Scale) and assessed in all patients with at least one molecular result. Secondary endpoints were a prognostic analysis of factors affecting maintenance of MMR at 6 months in learning and validation samples and the cost impact of stopping TKI therapy. We considered loss of haematological response, progress to accelerated-phase chronic myeloid leukaemia, or blast crisis as serious adverse events. This study presents the results of the prespecified interim analysis, which was done after the 6-month molecular relapse-free survival status was known for 200 patients. The study is ongoing and is registered with ClinicalTrials.gov, number NCT01596114. Findings: Between May 30, 2012, and Dec 3, 2014, we assessed 868 patients with chronic myeloid leukaemia for eligibility, of whom 758 were enrolled. Median follow-up of the 755 patients evaluable for molecular response was 27 months (IQR 21–34). Molecular relapse-free survival for these patients was 61% (95% CI 57–64) at 6 months and 50% (46–54) at 24 months. Of these 755 patients, 371 (49%) lost MMR after TKI discontinuation, four (1%) died while in MMR for reasons unrelated to chronic myeloid leukaemia (myocardial infarction, lung cancer, renal cancer, and heart failure), and 13 (2%) restarted TKI therapy while in MMR. A further six (1%) patients died in chronic-phase chronic myeloid leukaemia after loss of MMR and re-initiation of TKI therapy for reasons unrelated to chronic myeloid leukaemia, and two (<1%) patients lost MMR despite restarting TKI therapy. In the prognostic analysis in 405 patients who received imatinib as first-line treatment (learning sample), longer treatment duration (odds ratio [OR] per year 1·14 [95% CI 1·05–1·23]; p=0·0010) and longer deep molecular response durations (1·13 [1·04–1·23]; p=0·0032) were associated with increasing probability of MMR maintenance at 6 months. The OR for deep molecular response duration was replicated in the validation sample consisting of 171 patients treated with any TKI as first-line treatment, although the association was not significant (1·13 [0·98–1·29]; p=0·08). TKI discontinuation was associated with substantial cost savings (an estimated €22 million). No serious adverse events were reported. Interpretation: Patients with chronic myeloid leukaemia who have achieved deep molecular responses have good molecular relapse-free survival. Such patients should be considered for TKI discontinuation, particularly those who have been in deep molecular response for a long time. Stopping treatment could spare patients from treatment-induced side-effects and reduce health expenditure. Funding: ELN Foundation and France National Cancer Institute.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-6 av 6
Typ av publikation
tidskriftsartikel (5)
forskningsöversikt (1)
Typ av innehåll
övrigt vetenskapligt/konstnärligt (4)
refereegranskat (2)
Författare/redaktör
Saussele, Susanne (6)
Hjorth-Hansen, Henri ... (6)
Richter, Johan (5)
Olsson-Strömberg, Ul ... (5)
Ehrencrona, Hans (4)
visa fler...
Guilhot, Joelle (4)
Porkka, Kimmo (4)
Malm, Claes (3)
Höglund, Martin (3)
Lehmann, Soren (3)
Mayer, Jiri (3)
Själander, Anders (3)
Markevärn, Berit (3)
Ohm, Lotta (3)
Söderlund, Stina (3)
Almeida, Antonio (2)
Hochhaus, Andreas (2)
Kairisto, Veli (2)
Rousselot, Philippe (2)
Simonsson, Bengt (1)
Vestergaard, Hanne (1)
Kantarjian, Hagop M. (1)
Baccarani, Michele (1)
Rosti, Gianantonio (1)
Steegmann, Juan Luis (1)
Clark, Richard E. (1)
Pane, Fabrizio (1)
Niederwieser, Dietge ... (1)
Saglio, Giuseppe (1)
Cervantes, Francisco (1)
Guilhot, François (1)
Martinelli, Giovanni (1)
Deininger, Michael W ... (1)
Soverini, Simona (1)
Apperley, Jane F. (1)
Cortes, Jorge E. (1)
Hughes, Timothy P. (1)
Kim, Dong-Wook (1)
Larson, Richard A. (1)
Lipton, Jeffrey H. (1)
Mueller, Martin C. (1)
Radich, Jerald P. (1)
Schiffer, Charles (1)
Silver, Richard (1)
Goldman, John M. (1)
Hehlmann, Ruediger (1)
Panayiotidis, Panayi ... (1)
Martinez-Lopez, Joaq ... (1)
Janssen, Jeroen J W ... (1)
visa färre...
Lärosäte
Uppsala universitet (6)
Umeå universitet (3)
Lunds universitet (1)
Språk
Engelska (6)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (5)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy